Comparative Pharmacology
Head-to-head clinical analysis: ADVIL MIGRAINE LIQUI GELS versus DUEXIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL MIGRAINE LIQUI GELS versus DUEXIS.
ADVIL MIGRAINE LIQUI-GELS vs DUEXIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing the synthesis of prostaglandins involved in pain, inflammation, and fever.
DUEXIS is a combination of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, and famotidine, a histamine H2-receptor antagonist that decreases gastric acid secretion. Famotidine mitigates the risk of NSAID-induced gastric ulcers.
400 mg (two 200 mg Liqui-Gels) orally every 6 to 8 hours as needed; maximum 1200 mg per day.
One tablet (800 mg ibuprofen/26.6 mg famotidine) orally three times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1.8–3.5 hours). In clinical context, this short half-life supports dosing every 4–6 hours for acute migraine treatment, but drug effects may persist beyond this due to slow dissociation from COX enzymes.
Ibuprofen: 2-4 hours (terminal); requires every 6-8 hour dosing. Famotidine: 2.5-3.5 hours (normal renal function); prolonged to 20 hours or more in severe renal impairment (CrCl < 30 mL/min).
Renal excretion of unchanged drug and metabolites accounts for approximately 90% of an administered dose, with about 10% excreted in feces via bile. Less than 1% is excreted unchanged in urine; the remainder as conjugates and oxidative metabolites.
Ibuprofen: ~1% unchanged in urine, 14% as conjugated metabolites, remainder as oxidative metabolites; <1% excreted in feces. Famotidine: 65-70% unchanged in urine, 30-35% metabolized hepatic; <10% fecal.
Category C
Category C
NSAID
NSAID/H2 Antagonist Combination